Antigen presentation and HLA-DR expression by FK-506-treated human monocytes.
The novel macrolide immunosuppressant FK-506 demonstrated superior potency to cyclosporin A (CsA) in the inhibition of purified protein derivative (PPD)-induced human T-cell proliferation. Pulsing of monocytes with PPD for 24 hr in the presence of FK-506 did not impair their capacity to subsequently induced the proliferation of purified autologous T cells. In contrast, FK-506 profoundly inhibited the proliferative response of T cells to antigen-pulsed monocytes. Recombinant IL-2, but not IL-1, partially restored the proliferative response to PPD in the presence of the drug. FK-506 had no effect on basal or rIFN-gamma-induced expression of HLA-DR on monocytic cell line cells. These findings provide the first evidence that FK-506 can profoundly inhibit soluble antigen-induced human T-cell proliferation at concentrations which do not significantly impair the accessory function of mononuclear phagocytes.
Woo
J
J
Department of Pathology, University of Aberdeen, U.K.
Propper
D J
DJ
Thomson
A W
AW
D000900:Anti-Bacterial Agents / Q000494:pharmacology*; D000938:Antigen-Presenting Cells / Q000187:drug effects*; D003524:Cyclosporins / Q000494:pharmacology; D006684:HLA-DR Antigens / Q000032:analysis*; D006801:Humans; D007166:Immunosuppressive Agents / Q000494:pharmacology*; D007375:Interleukin-1 / Q000276:immunology; D007376:Interleukin-2 / Q000276:immunology; D008213:Lymphocyte Activation / Q000187:drug effects; D009000:Monocytes / Q000187:drug effects* / Q000276:immunology; D011994:Recombinant Proteins / Q000276:immunology; D013601:T-Lymphocytes / Q000276:immunology; D016559:Tacrolimus; D014373:Tuberculin / Q000276:immunology
D000900:Anti-Bacterial Agents; D003524:Cyclosporins; D006684:HLA-DR Antigens; D007166:Immunosuppressive Agents; D007375:Interleukin-1; D007376:Interleukin-2; D011994:Recombinant Proteins; D014373:Tuberculin; D016559:Tacrolimus